Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Liminatus Pharma Inc. (LIMN : NSDQ)

• Company Description    Liminatus Pharma LLC operates as a clinical-stage immuno-oncology company which develops novel cancer therapies. Liminatus Pharma LLC is based in LA Palma, California. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $0.17 Daily Weekly Monthly 20 Day Moving Average: 18,289,326 shares Shares Outstanding: 44.88 (millions) Market Capitalization: $7.60 (millions) Beta: 52 Week High: $33.66 52 Week Low: $0.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.17% -19.32% 12 Week -26.32% -31.88% Year To Date -72.23% -62.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2251 Stern Goodman Street Suite E - Fullerton,CA 92833 USA ph: 213-273-5453 fax: - None https://liminatuspharma.com

• General Corporate Information    Officers Chris Kim - Chief Executive Officer Scott Dam - Chief Financial Officer Eun Sook Lee - Director Nicholas Fernandez - Director Ji Yeon Baek - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 53271X108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 10/02/26 Share - Related Items Shares Outstanding: 44.88 Most Recent Split Date: (:1) Beta: Market Capitalization: $7.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -299.79 12/31/25 - -402.52 09/30/25 - -229.24 Current Ratio 03/31/26 - 0.96 12/31/25 - 0.05 09/30/25 - 0.42 Quick Ratio 03/31/26 - - 12/31/25 - 0.05 09/30/25 - 0.42 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.00 12/31/25 - -0.36 09/30/25 - -0.06 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©